BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
PHOENIX, April 25, 2017 -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “Company”) today announced that the Company will release its first quarter 2017 financial results on Tuesday, May 9, 2017, before the U.S. financial markets open.
Following the release of the financial results, Saeed Motahari, President and Chief Executive Officer, and Darryl S. Baker, Chief Financial Officer, will host a conference call at 10:00 a.m. Eastern Daylight Time.
Interested parties may participate in the conference call by dialing (844) 263-8304 (U.S.) or (213) 358-0958 (International), 5-10 minutes prior to the start of the call. A replay will be available shortly after the completion of the call for one week by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (International) and entering conference call ID number 14339975.
A live audio webcast and archive of the call will also be available at www.insysrx.com.
About Insys
Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, Insys is developing a pipeline of products intending to address unmet medical needs and the clinical shortcomings of existing commercial products. Insys currently markets one product, SUBSYS® (fentanyl sublingual spray) but has received approval for the marketing of SYNDROS™ (dronabinol oral solution), a proprietary, orally administered liquid formulation of dronabinol that Insys believes has distinct advantages over the current formulation of dronabinol in soft gel capsule. Insys is committed to developing medications for potentially treating addiction to opioids, opioid overdose, epilepsy, and other disease areas with high unmet need.
SUBSYS® and SYNDROS™ are trademarks of Insys Development Company, Inc., a subsidiary of Insys Therapeutics, Inc.
Contact: Lisa M. Wilson T: 212-452-2793 E: [email protected]
